300677.SZ
Intco Medical Technology Co., Ltd. [300677.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
300677.SZ Stock Summary
Top 10 Correlated ETFs
300677.SZ
Top 10 Correlated Stocks
300677.SZ
In the News
300677.SZ Financial details
Company Rating
Buy
Market Cap
18.07B
Income
1.7B
Revenue
8.18B
Book val./share
28.59
Cash/share
13.55
Dividend
0.75
Dividend %
2.74%
Employees
9.12K
Optionable
No
Shortable
Yes
Earnings
22 Apr 2022
P/E
23.88
Forward P/E
-
PEG
-3.06
P/S
2.92
P/B
0.96
P/C
2.02
P/FCF
-32.07
Quick Ratio
4.15
Current Ratio
5.11
Debt / Equity
0.26
LT Debt / Equity
0
-
-
EPS (TTM)
3.21
EPS next Y
-
EPS next Q
-
EPS this Y
-7.19%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
103.58%
Revenue last 5Y
56.13%
Revenue Q/Q
1.32%
EPS Q/Q
-25.92%
-
-
-
-
SMA20
-6.1%
SMA50
15.46%
SMA100
14.45%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
4%
ROC
0.05%
Gross Margin
14%
Oper. Margin
16%
Profit Margin
12%
Payout
67%
Shs Outstand
659.77M
Shs Float
423.04M
-
-
-
-
Target Price
-
52W Range
18.68-40.25
52W High
-31.5%
52W Low
+52.22%
RSI
66.66
Rel Volume
2.3
Avg Volume
11.77M
Volume
27.07M
Perf Week
13.08%
Perf Month
3.24%
Perf Quarter
42.41%
Perf Half Y
36.32%
-
-
-
-
Beta
0.87799
-
-
Volatility
1.1%, 1.07%
Prev Close
8.56%
Price
27.4
Change
9.78%
300677.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.69 | 4.31 | 4.72 | 28.94 | 29.73 | |
| Net income per share | 0.39 | 0.41 | 0.4 | 14.65 | 13.6 | |
| Operating cash flow per share | 0.66 | 0.42 | 0.75 | 17.96 | 15.89 | |
| Free cash flow per share | 0.09 | -0.28 | -0.47 | 11.92 | 5.92 | |
| Cash per share | 0.77 | 1.96 | 1.98 | 13.36 | 15.15 | |
| Book value per share | 2.92 | 2.9 | 3.35 | 19.54 | 29.05 | |
| Tangible book value per share | 2.83 | 2.69 | 2.96 | 19.02 | 28.36 | |
| Share holders equity per share | 2.92 | 2.9 | 3.35 | 19.54 | 29.05 | |
| Interest debt per share | 0.71 | 1.89 | 2.37 | 0.63 | 0.57 | |
| Market cap | 3.41B | 2.25B | 2.58B | 42.71B | 25.68B | |
| Enterprise value | 3.38B | 2.21B | 2.98B | 37.99B | 20.97B | |
| P/E ratio | 23.52 | 12.56 | 14.45 | 6.1 | 3.46 | |
| Price to sales ratio | 1.95 | 1.19 | 1.24 | 3.09 | 1.58 | |
| POCF ratio | 13.79 | 12.12 | 7.82 | 4.97 | 2.96 | |
| PFCF ratio | 96.78 | -18.34 | -12.46 | 7.49 | 7.93 | |
| P/B Ratio | 3.14 | 1.77 | 1.74 | 4.57 | 1.62 | |
| PTB ratio | 3.14 | 1.77 | 1.74 | 4.57 | 1.62 | |
| EV to sales | 1.93 | 1.17 | 1.43 | 2.75 | 1.29 | |
| Enterprise value over EBITDA | 13.95 | 7.35 | 9.21 | 4.46 | 2.33 | |
| EV to operating cash flow | 13.64 | 11.89 | 9.03 | 4.42 | 2.42 | |
| EV to free cash flow | 95.74 | -17.99 | -14.4 | 6.66 | 6.48 | |
| Earnings yield | 0.04 | 0.08 | 0.07 | 0.16 | 0.29 | |
| Free cash flow yield | 0.01 | -0.05 | -0.08 | 0.13 | 0.13 | |
| Debt to equity | 0.52 | 0.9 | 1.01 | 0.37 | 0.28 | |
| Debt to assets | 0.34 | 0.47 | 0.5 | 0.27 | 0.22 | |
| Net debt to EBITDA | -0.15 | -0.14 | 1.24 | -0.56 | -0.52 | |
| Current ratio | 1.62 | 1.34 | 1.78 | 3.82 | 5.17 | |
| Interest coverage | 14.87 | 13.65 | 8 | 405.75 | 493.53 | |
| Income quality | 1.71 | 1.04 | 1.85 | 1.23 | 1.17 | |
| Dividend Yield | 0 | 0.01 | 0.02 | 0 | 0.04 | |
| Payout ratio | 0.1 | 0.16 | 0.31 | 0.02 | 0.14 | |
| Sales general and administrative to revenue | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.02 | 0.04 | 0.07 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.86 | -1.66 | -1.63 | -0.34 | -0.63 | |
| Capex to revenue | -0.12 | -0.16 | -0.26 | -0.21 | -0.34 | |
| Capex to depreciation | -3.25 | -3.88 | -5.82 | -20.63 | -14.77 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.05 | 5.17 | 5.52 | 80.26 | 94.28 | |
| ROIC | 0.21 | 0.34 | 0.13 | 3.52 | 0.8 | |
| Return on tangible assets | 0.09 | 0.08 | 0.06 | 0.56 | 0.37 | |
| Graham Net | -0.54 | -0.43 | -1.14 | 6.95 | 7.9 | |
| Working capital | 328.26M | 367.74M | 676.5M | 6.28B | 8.68B | |
| Tangible asset value | 1.06B | 1.18B | 1.31B | 9.09B | 15.49B | |
| Net current asset value | 284.15M | 289.09M | 53.99M | 5.02B | 6.26B | |
| Invested capital | 0.23 | 0.64 | 0.69 | 0.03 | 0.02 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 217.05M | 220.06M | 257.43M | 576.94M | 1.05B | |
| Average inventory | 151.8M | 184.71M | 220.2M | 540.36M | 963.22M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 61.94 | 55.78 | 69.67 | 72.92 | 72.25 | |
| Days of inventory on hand | 45.07 | 53.22 | 54.57 | 72.18 | 63 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 5.89 | 6.54 | 5.24 | 5.01 | 5.05 | |
| Inventory turnover | 8.1 | 6.86 | 6.69 | 5.06 | 5.79 | |
| ROE | 0.13 | 0.14 | 0.12 | 0.75 | 0.47 | |
| Capex per share | -0.57 | -0.7 | -1.22 | -6.04 | -9.96 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-06-30 | 2021-09-30 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 7.64 | 5.76 | 4.11 | 2.61 | 2.64 | |
| Net income per share | 4.15 | 2.06 | 0.15 | 0.57 | 0.42 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 3.52 | 0.64 | -0.45 | -0.59 | 0.03 | |
| Cash per share | 16.57 | 17.06 | 14.53 | 14.07 | 13.55 | |
| Book value per share | 27.74 | 29.8 | 28.67 | 28.44 | 28.59 | |
| Tangible book value per share | 27.01 | 29.05 | 27.95 | 27.69 | 27.97 | |
| Share holders equity per share | 27.74 | 29.8 | 28.67 | 28.44 | 28.59 | |
| Interest debt per share | 1 | 1.15 | 1.09 | 1.62 | 0.92 | |
| Market cap | 34.89B | 24.59B | 20.92B | 14.12B | 11.09B | |
| Enterprise value | 28B | 19.69B | 16.7B | 9.87B | 5.26B | |
| P/E ratio | 4.07 | 5.78 | 62.63 | 11.07 | 11.74 | |
| Price to sales ratio | 8.86 | 8.27 | 9.14 | 9.72 | 7.54 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 19.19 | 74.68 | -83.53 | -42.65 | 620.88 | |
| P/B Ratio | 2.44 | 1.6 | 1.31 | 0.89 | 0.7 | |
| PTB ratio | 2.44 | 1.6 | 1.31 | 0.89 | 0.7 | |
| EV to sales | 7.11 | 6.63 | 7.3 | 6.8 | 3.57 | |
| Enterprise value over EBITDA | 11.08 | 17.51 | 146.53 | 23.41 | 16.06 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 15.4 | 59.82 | -66.68 | -29.83 | 294.47 | |
| Earnings yield | 0.06 | 0.04 | 0 | 0.02 | 0.02 | |
| Free cash flow yield | 0.05 | 0.01 | -0.01 | -0.02 | 0 | |
| Debt to equity | 0.32 | 0.31 | 0.27 | 0.3 | 0.26 | |
| Debt to assets | 0.24 | 0.23 | 0.21 | 0.23 | 0.2 | |
| Net debt to EBITDA | -2.73 | -4.35 | -37.02 | -10.07 | -17.8 | |
| Current ratio | 5.33 | 5.22 | 5.55 | 4.59 | 5.11 | |
| Interest coverage | 771.07 | 255.07 | 21.44 | 61.29 | 54.85 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0.03 | 0 | 0 | 0.03 | 0 | |
| Payout ratio | 0.49 | 0.01 | 0.04 | 1.31 | 0.03 | |
| Sales general and administrative to revenue | 0 | 0.09 | 0.05 | -0.02 | 0.17 | |
| Research and developement to revenue | 0.02 | 0.03 | 0.03 | 0.05 | 0.04 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.45 | -0.43 | -0.29 | -0.47 | -0.34 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 50.91 | 37.18 | 9.84 | 19.15 | 16.52 | |
| ROIC | 0.64 | 0.13 | 0.01 | 0.03 | 0.03 | |
| Return on tangible assets | 0.12 | 0.05 | 0 | 0.02 | 0.01 | |
| Graham Net | 8.52 | 8.8 | 7.54 | 6.66 | 6.92 | |
| Working capital | 8.99B | 9.32B | 8.56B | 7.81B | 7.47B | |
| Tangible asset value | 13.94B | 14.99B | 15.55B | 15.41B | 15.57B | |
| Net current asset value | 6.47B | 6.76B | 6.09B | 5.27B | 5.15B | |
| Invested capital | 0.04 | 0.04 | 0.04 | 0.06 | 0.03 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 920.34M | 1.07B | 0 | 948.48M | 816.47M | |
| Average inventory | 996.2M | 954.99M | 0 | 1.05B | 1.03B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 78.12 | 66.19 | 47.05 | 68.22 | 46.38 | |
| Days of inventory on hand | 69.63 | 59.22 | 44.47 | 87.33 | 57.86 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.15 | 1.36 | 1.91 | 1.32 | 1.94 | |
| Inventory turnover | 1.29 | 1.52 | 2.02 | 1.03 | 1.56 | |
| ROE | 0.15 | 0.07 | 0.01 | 0.02 | 0.01 | |
| Capex per share | -3.47 | -2.46 | -1.2 | -1.23 | -0.91 |
300677.SZ Frequently Asked Questions
What is Intco Medical Technology Co., Ltd. stock symbol ?
Intco Medical Technology Co., Ltd. is a CN stock and trading under the symbol 300677.SZ
What is Intco Medical Technology Co., Ltd. stock quote today ?
Intco Medical Technology Co., Ltd. stock price is $27.4 today.
Is Intco Medical Technology Co., Ltd. stock public?
Yes, Intco Medical Technology Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 11.77M
- Market Capitalization 18.07B
- Employee 9.12K
- CEO Ms. Qiong Chen
- Headquarters Zibo,CN
- IPO Date 2017-07-24
-
Website
https://www.intcomedical.com.cn 
Intco Medical Technology Co., Ltd. engages in the research and development, production, and sale of medical disposable products and durable medical equipment in China and internationally. The company offers gloves; face masks and shields; ECG electrode; apparels, such as isolation gowns; hand sanitizer gel and spray; grounding pads; electrosurgical pencil; ESU cable and tip cleaner; and tens electrode. It also provides wheelchairs, scooters, and other medical equipment; hot and cold products, emergency treatment products, and mother and baby products; and home care products. The company was formerly known as Intco Medical Technology Co., Ltd. and changed its name to Intco Medical Technology Co., Ltd. in January 2020. Intco Medical Technology Co., Ltd. was founded in 2009 and is based in Zibo, China.
